DAYTON, Ohio--(BUSINESS WIRE)--May 15, 2017--
Midmark Corporation, a leading medical solutions provider for ambulatory
care, and Masimo (NASDAQ: MASI), a global leader in innovative
noninvasive monitoring technologies, today announced a partnership
focused on improving the accuracy and efficiency of vital signs
acquisition in the clinical space.
This Smart News Release features multimedia. View the full release here:
Midmark IQvitals® Zone™ with Masimo SET® (Photo: Business Wire)
With this partnership, Masimo
SET® pulse oximetry technology is now an available option
with Midmark’s recently introduced Midmark
IQvitals® Zone™, the industry’s first monitoring device
to feature Bluetooth® low energy technology for
auto-connecting during the vitals acquisition process. IQvitals Zone
devices equipped with Masimo SET® technology provide
clinicians with accurate, real-time vital signs information including
oxygen saturation (SpO2), pulse rate (PR) and perfusion index
(Pi) to facilitate timely clinical decisions.
Midmark IQvitals Zone changes the traditional workflow in vitals
acquisition by establishing a direct wireless connection between vital
signs measurement and the caregiver’s tablet or laptop. The vital signs
monitor automatically connects with the appropriate equipment when the
caregiver places a tablet or laptop on the multi-use work surface or
near the monitoring device and initiates vitals acquisition. When the
equipment is connected, caregivers can take patient vitals, review
results and seamlessly import the information to an electronic medical
records (EMR) system directly from their laptop or tablet.
“Masimo has long been a leader in creating new technologies to improve
patient care,” said Kurt Forsthoefel, Marketing Director, Medical
Products and Services, Midmark. “Midmark and Masimo are two companies
ultimately focused on improving outcomes and the healthcare experience,
and we’re looking forward to working together to provide caregivers with
innovative technologies that enhance patient-caregiver interaction and
improve outcomes at the point of care.”
“Like Midmark, Masimo is focused on developing solutions which can help
caregivers enhance the quality and process of care,” said Rick Fishel,
President of Worldwide OEM Business and Strategic Development for
Masimo. “We are confident that Masimo’s proven portfolio of accurate and
timely measurements, in combination with Midmark’s innovative solutions,
will help physicians and caregivers deliver quality care and enhance
clinical work flow.”
The Midmark IQvitals Zone device with Masimo SETpulse
oximetry technology is one part of a fully
connected point of care ecosystem that promotes well-coordinated
patient experiences. More information about how IQvitals Zone brings the
industry one step closer to a connected ecosystem can be found in the
new white paper “Zone
Technology: Connecting Vitals Acquisition within the Point of Care
Ecosystem” in the Midmarkcontent
and news library.
Midmark Corporation, a privately held company founded in 1915, is a
leading provider of medical,
equipment and technologies. Our nearly 1,700 teammates worldwide are
passionate, courageous leaders focused on making a positive difference
in the lives we touch by improving the experience between patients and
their caregivers. Headquartered in Dayton, Ohio, Midmark maintains
production and administrative offices in Versailles, Ohio, as well as
seven other locations in the United States and international
subsidiaries in India, Italy and the United Kingdom. To learn more about
Midmark, visit midmark.com.
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® has also been
shown to help clinicians reduce severe retinopathy of prematurity in
neonates,1 improve CCHD screening in newborns,2
and, when used for continuous monitoring with Masimo Patient SafetyNet™*
in post-surgical wards, reduce rapid response activations and costs.3,4,5
Masimo SET® is estimated to be used on more than 100 million
patients in leading hospitals and other healthcare settings around the
world,6 including 17 of the top 20 hospitals listed in the
2016-17 U.S. News and World Report Best Hospitals Honor Roll.7
In 2005, Masimo introduced rainbow® Pulse CO-Oximetry
technology, allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®),
and more recently, Pleth Variability Index (PVi®) and Oxygen
Reserve Index (ORi™), in addition to SpO2, pulse rate, and
perfusion index (PI). In 2014, Masimo introduced Root®, an
intuitive patient monitoring and connectivity platform with the Masimo
Open Connect™ (MOC-9™) interface, enabling other companies to augment
Root with new features and measurement capabilities. Masimo is also
taking an active leadership role in mHealth with products such as the
Radius-7™ wearable patient monitor, iSpO2® pulse
oximeter for smartphones, and the MightySat™ fingertip pulse oximeter.
Additional information about Masimo and its products may be found at www.masimo.com.
Published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
*The use of the trademark Patient SafetyNet is under license from
University HealthSystem Consortium.
Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm
Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;338.
Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue
Events and Intensive Care Unit Transfers: A Before-And-After
Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia
Patient Safety Foundation Newsletter. Spring-Summer 2012.
McGrath SP et al. Surveillance Monitoring Management for General Care
Units: Strategy, Design, and Implementation. The Joint Commission
Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
Estimate: Masimo data on file.
Forward-Looking Statements – Masimo
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo SET®. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including Masimo SET®, contribute to positive
clinical outcomes and patient safety; as well as other factors discussed
in the "Risk Factors" section of our most recent reports filed with the
Securities and Exchange Commission ("SEC"), which may be obtained for
free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170515005495/en/
Content & Social Media